A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer

Annals of Oncology

Volumn 26, Issue 6, 2015, Pages 1194-1200

  Deplanque, Gaël ^a   Demarchi, M ^b   Hebbar, M ^c   Flynn, P ^d   Melichar, B ^e   Atkins, J ^f   Nowara, E ^g   Moye L ^h   Piquemal, D ⁱ   Ritter, D ⁱ   Dubreuil, P ^j,k,l,m,n   Mansfield, C D ⁿ   Acin, Y ⁿ   Moussy, A ⁿ   Hermine, O ^{m,n,o,p,q,r,s}   Hammel, P ^t  

^a SAINT JOSEPH HOSPITAL   (France)

^b UNIVERSITY HOSPITAL OF BESANÇON   (France)

^c Lille1 University   (France)

^d Park Nicollet Institute   (United States)

^e PALACKÝ UNIVERSITY   (Czech Republic)

^f Southeastern Medical Oncology Center   (United States)

^g INSTITUTE OF ONCOLOGY   (Poland)

^h UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

ⁱ Acobiom   (France)

^j AIX MARSEILLE UNIVERSITY   (France)

^k INSTITUT PAOLI CALMETTES   (France)

^l AIX MARSEILLE UNIVERSITY   (France)

^m CNRS   (France)

ⁿ AB Science   (France)

^o HÔPITAL NECKER ENFANTS MALADES   (France)

^p INSERM   (France)

^q PARIS DESCARTES SORBONNE PARIS CITÉ UNIVERSITY   (France)

^r Laboratory of Excellence   (France)

^s French Reference Center for Mastocytosis   (France)

^t BEAUJON HOSPITAL   (France)

more..

Author keywords

ACOX1; Genetic biomarker; Pain; Pancreatic cancer; PDAC; Tyrosine kinase inhibitor

Indexed keywords

GEMCITABINE; MASITINIB; PLACEBO; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; OXIDOREDUCTASE; PROTEIN KINASE INHIBITOR; THIAZOLE DERIVATIVE; TUMOR MARKER;

ACOX1 GENE; ADVANCED CANCER; ANEMIA; ARTICLE; BACKACHE; BLOOD SAMPLING; CANCER SURVIVAL; CONSTIPATION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEVER; GENE OVEREXPRESSION; HEMATOLOGIC DISEASE; HUMAN; HYPOKALEMIA; INFECTION; INTENTION TO TREAT ANALYSIS; LUNG EMBOLISM; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PHARMACOGENOMICS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RASH; THROMBOCYTOPENIA; THROMBOSIS; TUMOR GENE; VISUAL ANALOG SCALE; VOMITING; ADULT; AGED; ANALOGS AND DERIVATIVES; CARCINOMA, PANCREATIC DUCTAL; CLINICAL TRIAL; COMPARATIVE STUDY; ENZYMOLOGY; EUROPE; FEMALE; GENETICS; MALE; MIDDLE AGED; MORTALITY; PANCREATIC NEOPLASMS; PATHOLOGY; PERSONALIZED MEDICINE; PHARMACOGENETICS; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME; UNITED STATES; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; CARCINOMA, PANCREATIC DUCTAL; DEOXYCYTIDINE; EUROPE; FEMALE; HUMANS; INTENTION TO TREAT ANALYSIS; MALE; MIDDLE AGED; OXIDOREDUCTASES; PANCREATIC NEOPLASMS; PHARMACOGENETICS; PRECISION MEDICINE; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PROTEIN KINASE INHIBITORS; RISK FACTORS; THIAZOLES; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84938084839     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv133     Document Type: Article

References (12)

1. Heinemann V, Boeck S, Hinke A et al. Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer 2008; 8:82.
2. Von Hoff DD, Ervin T, Arena FP et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013; 369(18):1691-1703.
3. Moore MJ, Goldstein D, Hamm J et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25(15):1960-1966.
4. Humbert M, Castéran N, Letard S et al. Masitinib combined with standard gemcitabine chemotherapy: in vitro and in vivo studies in human pancreatic tumour cell lines and ectopic mouse model. PLoS ONE 2010; 5: e9430.
5. Mitry E, Hammel P, Deplanque G et al. Safety and activity of masitinib in combination with gemcitabine in patients with advanced pancreatic cancer. Cancer Chemother Pharmacol 2010; 66(2):395-403.
6. Zelvyte I, Ohlsson B, Axelson J, Janciauskiene S. Diverse responses between human pancreatic cancer cell lines to native alpha 1-antitrypsin and its C-terminal fragment. Anticancer Res 2003; 23(3B):2267-2273.
7. Winter JM, Tang LH, Klimstra DS et al. A novel survival-based tissue microarray of pancreatic cancer validates MUC1 and mesothelin as biomarkers. PLoS One 2012; 7(7): e40157.
8. Chang DZ, Ma Y, Ji B et al. Mast cells in tumor microenvironment promotes the in vivo growth of pancreatic ductal adenocarcinoma. Clin Cancer Res 2011; 17(22):7015-7023.
9. Protti MP, De Monte L. Immune infiltrates as predictive markers of survival in pancreatic cancer patients. Front Physiol 2013; 4:210.
10. Dubreuil P, Letard S, Ciufolini M et al. Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT. PLoS One 2009; 4(9): e7258.
11. Demir IE, Schorn S, Schremmer-Danninger E et al. Perineural mast cells are specifically enriched in pancreatic neuritis and neuropathic pain in pancreatic cancer and chronic pancreatitis. PLoS One 2013; 8(3): e60529.
12. Maltby S, Khazaie K, McNagny KM. Mast cells in tumor growth: angiogenesis, tissue remodelling and immune-modulation. Biochim Biophys Acta 2009; 1796(1):19-26.